Juvederm is a dermal filler. It is not an alternative to one. "Dermal filler" is the name of the whole category. Juvederm is one brand family inside it, made by Allergan Aesthetics. Asking whether to have Juvederm or dermal filler is like asking whether to buy an iPhone or a smartphone.
The category splits by material, and that is the split that actually matters. There are four chemically distinct types on the US market. The first is hyaluronic acid gels, which is where Juvederm sits alongside Restylane, RHA, Belotero, Revanesse Versa and Evolysse. The second is calcium hydroxylapatite, which is Radiesse. The third is poly-L-lactic acid, which is Sculptra. The fourth is polymethylmethacrylate microspheres, which is Bellafill.
The most important consequence of that split is reversibility. Hyaluronidase, the enzyme used to dissolve filler, works on hyaluronic acid. It does nothing to Radiesse, Sculptra or Bellafill. Bellafill's microspheres are not absorbed by the body at all. Surgical excision is the only definitive way to remove them.
"Juvederm" on its own does not name a product either. Juvederm Ultra XC, Ultra Plus XC, Voluma XC, Vollure XC, Volbella XC, Volux XC and Skinvive are separate FDA-approved products. Each has its own indications, its own trials and its own duration figures. Juvederm Ultra XC is approved for lips. Juvederm Ultra Plus XC is not. A number from one does not belong to another.
Ultra XC, Ultra Plus XC, Voluma XC, Vollure XC, Volbella XC, Volux XC and Skinvive.
Hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid and polymethylmethacrylate.
Every Juvederm product in the US is a hyaluronic acid gel. The "XC" products all contain 0.3% lidocaine; Juvederm Ultra and Ultra Plus without the "XC" do not.
Hyaluronic acid gels fill on the day. Sculptra is poly-L-lactic acid, a biostimulator that provokes collagen over months rather than filling. Radiesse is calcium hydroxylapatite in a gel carrier. Bellafill is permanent acrylic microspheres in a bovine collagen carrier.
Restylane is Galderma's family; RHA is Teoxane's, marketed in the US by Revance; Belotero and Radiesse are Merz; Revanesse is Prollenium; Evolysse is Evolus and Symatese.
Hyaluronidase breaks down hyaluronic acid. In laboratory testing Juvederm gels were among the most resistant, needing several times more enzyme than some others within an hour.
Hyaluronidase has no enzymatic target in calcium hydroxylapatite, poly-L-lactic acid or polymethylmethacrylate. For Radiesse and Sculptra the realistic options are time, saline infiltration with mechanical disruption, steroids and rarely surgery. For Bellafill it is surgery. There is no approved reversal agent for any of the three.
Juvederm Voluma XC in the cheeks: 85.6% responders at month 6, 85.2% at 12 months, 67.1% at 24 months. Juvederm Ultra XC in the lips: 79.1% at month 3, 56.4% at month 12. Juvederm Vollure XC in nasolabial folds: 93.2% at month 6, 59.4% at month 18.
Restylane Kysse reported 60% responders at week 48; Restylane Eyelight 63.5% at month 12. Bellafill's microspheres are permanent by design. None of these figures can be compared with each other — different products, different trials, different manufacturer-developed scales.
Lips: Ultra XC and Volbella XC only. Cheeks, chin and temples: Voluma XC. Nasolabial folds and facial wrinkles: Ultra XC, Ultra Plus XC, Vollure XC. Jawline definition: Volux XC. Cheek smoothness and, since June 2026, neck lines: Skinvive. Under-eye hollowing: Volbella XC.
Some areas have several approved options — four separate products are approved for the under-eye hollow. Some have one obvious option: Restylane Lyft with Lidocaine holds the only hyaluronic acid approval for the backs of the hands in this list, and it is the only non-facial hyaluronic acid indication in the US record.
Neither appears in the FDA documents, which describe both simply as hyaluronic acid crosslinked with BDDE.
NASHA, XpresHAn, CPM and Resilient HA are manufacturer trademarks, not scientific classifications and not FDA-recognised categories.
Allergan does not publish patient prices, and nor do Galderma, Merz or Teoxane.
The American Society of Plastic Surgeons' last published averages, for 2023, were $715 for hyaluronic acid fillers and $901 for non-hyaluronic acid fillers such as Radiesse, Sculptra and Bellafill. Those are per-procedure surgeon fees excluding facility and anaesthesia, pooling many products and facial areas, and ASPS stopped publishing minimally invasive fees after 2023.
Less than the marketing suggests, and not the things people expect.
Hyaluronic acid concentration barely varies and does not track with strength: Juvederm Volbella XC is 15 mg/ml and Juvederm Volux XC is 25 mg/ml. So within one family the range is real. But Restylane Lyft, Contour, Kysse, Refyne, Defyne and Eyelight are all 20 mg/ml, and they all behave completely differently. Concentration is a poor differentiator. The real variables are crosslinking and gel architecture. Those are proprietary.
Lidocaine is close to universal: Almost every product carries 0.3% lidocaine. There are two sets of exceptions in the US. The first is the base versions sold without it: Restylane, Belotero Balance, Revanesse Versa, and Juvederm Ultra and Ultra Plus without the "XC". The second is the RHA "Mepi" line, which uses mepivacaine instead.
The platform names are trademarks: Vycross, Hylacross, NASHA, XpresHAn, CPM, Resilient HA and Cold-X are manufacturer terms for proprietary manufacturing processes. None of them appears in the FDA documents, which describe every one of these products in the same generic chemical terms. They are useful shorthand for a company's own range. They are not scientific categories. They do not license comparisons across brands.
One documented physical differentiator is worth knowing. Restylane Silk has an FDA-recorded gel particle size of 50 to 220 microns at the median, the smallest in that range. That kind of figure comes from the approval documents. It is a defensible basis for comparison in a way that circulating firmness charts are not.
Most fillers have only been tested against no treatment. Their trials say nothing about how they compare with each other. A few have been tested against a named competitor. Those results are consistently undramatic.
The best-designed of them compared Restylane Contour against Juvederm Voluma XC in the cheeks. It had 210 people in the comparative arm, randomised and evaluator-blinded, across 17 US sites. It was a non-inferiority design and it met its margin. A non-inferiority result means a product was shown not to be meaningfully worse. It is not a win.
The lip trial for Juvederm Volbella XC used Restylane-L as its active control, with 168 people on Volbella and 56 on the comparator. At the primary timepoint the responder rates were 80.3% and 70.8%. The approval documents do not present that as a superiority finding. The group sizes were three to one. It should not be read as one product beating another.
The Restylane Refyne and Defyne trials were also run against an approved hyaluronic acid comparator. In raw responder terms the comparator was numerically higher at every timepoint. Both trials met their non-inferiority margins. Again, nobody won.
Two products can both be called dermal fillers and be almost nothing alike.
Sculptra does not fill: It is poly-L-lactic acid: tiny particles of a biodegradable material. It works by provoking the body to lay down collagen over weeks to months. Nothing looks different on the day. It is a biostimulator. It is approved for nasolabial folds and other facial wrinkles, and for fine lines and wrinkles in the cheek region.
Radiesse is a mineral: Calcium hydroxylapatite microspheres suspended in a gel carrier, approved for nasolabial folds and, in later supplements, for the backs of the hands and the jawline.
Bellafill is permanent: Its polymethylmethacrylate microspheres are, in the FDA's own words, "not absorbed by the body." The bovine collagen carrier resorbs over roughly one to three months. The microspheres stay. Its 2006 approval required a skin test for bovine collagen sensitivity before injection.
All three carry the same serious risk as hyaluronic acid fillers: filler entering an artery. And none of them can be dissolved. If reversibility matters to you, that is the single most important line in the category. It is invisible if you think of "dermal filler" as one thing.
Any change in vision, blurred vision or loss of vision in one or both eyes
Sudden severe pain, or pain out of proportion to the procedure
Skin turning white or pale, then dusky, mottled or net-patterned
Weakness, drooping, slurred speech or any other stroke-like symptom
These can mean filler has entered or blocked an artery, which is a risk of every filler regardless of brand or material. Published guidance treats a suspected blockage of an artery to the eye as a same-hour emergency, and the most cited window for reperfusion is 90 minutes, with the American Society for Dermatologic Surgery noting newer literature suggesting it may be as little as 10 to 15 minutes. Pain is not a reliable warning — it was mild or absent in 47% of intravascular injections reported in a survey of experienced injectors.
Swelling is still increasing after the first few days instead of settling
A lump forms and does not settle, or appears weeks or months later
Redness spreads outward from the injection site, or you develop a fever
Tenderness or firmness appears late, particularly after an illness, a vaccination or dental work
Filler looks like it has moved from where it was placed
A treated area starts to look bluish or grey, which can happen when hyaluronic acid gel sits too superficially